Morgan Stanley’s vTv Therapeutics VTVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $45.8K | Buy |
1,155
+178
| +18% | +$6.46K | ﹤0.01% | 6452 |
|
|
2025
Q4 | $39.1K | Buy |
977
+231
| +31% | +$6.43K | ﹤0.01% | 6503 |
|
|
2025
Q3 | $17.4K | Hold |
746
| – | – | ﹤0.01% | 6729 |
|
|
2025
Q2 | $11.2K | Hold |
746
| – | – | ﹤0.01% | 6826 |
|
|
2025
Q1 | $12.9K | Sell |
746
-400
| -35% | -$6.68K | ﹤0.01% | 6728 |
|
|
2024
Q4 | $15.8K | Buy |
1,146
+306
| +36% | +$4.53K | ﹤0.01% | 6645 |
|
|
2024
Q3 | $11.4K | Hold |
840
| – | – | ﹤0.01% | 6679 |
|
|
2024
Q2 | $14.8K | Hold |
840
| – | – | ﹤0.01% | 6552 |
|
|
2024
Q1 | $19.8K | Sell |
840
-840
| -50% | -$10.7K | ﹤0.01% | 6495 |
|
|
2023
Q4 | $19.3K | Buy |
1,680
+844
| +101% | +$11.9K | ﹤0.01% | 6670 |
|
|
2023
Q3 | $16K | Hold |
836
| – | – | ﹤0.01% | 6550 |
|
|
2023
Q2 | $24.7K | Hold |
836
| – | – | ﹤0.01% | 6496 |
|
|
2023
Q1 | $27K | Hold |
836
| – | – | ﹤0.01% | 6518 |
|
|
2022
Q4 | $22.2K | Hold |
836
| – | – | ﹤0.01% | 6647 |
|
|
2022
Q3 | $32K | Hold |
836
| – | – | ﹤0.01% | 6599 |
|
|
2022
Q2 | $25K | Sell |
836
-43
| -5% | -$1.1K | ﹤0.01% | 6905 |
|
|
2022
Q1 | $25K | Sell |
879
-4,302
| -83% | -$129K | ﹤0.01% | 7051 |
|
|
2021
Q4 | $206K | Buy |
5,181
+3,209
| +163% | +$172K | ﹤0.01% | 6050 |
|
|
2021
Q3 | $121K | Buy |
1,972
+1,053
| +115% | +$79.4K | ﹤0.01% | 6266 |
|
|
2021
Q2 | $83K | Buy |
919
+864
| +1,571% | +$87.5K | ﹤0.01% | 6435 |
|
|
2021
Q1 | $6K | Sell |
55
-198
| -78% | -$19.5K | ﹤0.01% | 7070 |
|
|
2020
Q4 | $19K | Buy |
253
+213
| +533% | +$16.3K | ﹤0.01% | 6452 |
|
|
2020
Q3 | $3K | Sell |
40
-48
| -55% | -$4.22K | ﹤0.01% | 6530 |
|
|
2020
Q2 | $8K | Buy |
88
+75
| +577% | +$7.41K | ﹤0.01% | 6221 |
|
|
2020
Q1 | $1K | Sell |
13
-117
| -90% | -$11.3K | ﹤0.01% | 6495 |
|
|
2019
Q4 | $9K | Sell |
130
-104
| -44% | -$6.32K | ﹤0.01% | 6293 |
|
|
2019
Q3 | $14K | Sell |
234
-232
| -50% | -$13.1K | ﹤0.01% | 6113 |
|
|
2019
Q2 | $27K | Sell |
466
-12
| -3% | -$720 | ﹤0.01% | 5833 |
|
|
2019
Q1 | $33K | Buy |
+478
| New | +$46.4K | ﹤0.01% | 5839 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | -$93 | – | 6747 |
|
|
2018
Q3 | $0 | Sell |
1
-609
| -100% | -$28.6K | ﹤0.01% | 6816 |
|
|
2018
Q2 | $38K | Sell |
610
-208
| -25% | -$15.4K | ﹤0.01% | 5986 |
|
|
2018
Q1 | $133K | Buy |
818
+6
| +0.7% | +$1.47K | ﹤0.01% | 5628 |
|
|
2017
Q4 | $195K | Sell |
812
-9
| -1% | -$2.02K | ﹤0.01% | 5416 |
|
|
2017
Q3 | $197K | Buy |
821
+26
| +3% | +$5.18K | ﹤0.01% | 5360 |
|
|
2017
Q2 | $158K | Buy |
795
+69
| +10% | +$14.4K | ﹤0.01% | 5451 |
|
|
2017
Q1 | $190K | Sell |
726
-160
| -18% | -$36.5K | ﹤0.01% | 5342 |
|
|
2016
Q4 | $170K | Buy |
886
+556
| +168% | +$128K | ﹤0.01% | 5403 |
|
|
2016
Q3 | $95K | Buy |
+330
| New | +$79.5K | ﹤0.01% | 5327 |
|
|
2016
Q1 | – | Sell |
-3
| Closed | -$1K | – | 6727 |
|
|
2015
Q4 | $1K | Sell |
3
-3,027
| -100% | -$849K | ﹤0.01% | 6581 |
|
|
2015
Q3 | $790K | Buy |
+3,030
| New | +$1.06M | ﹤0.01% | 4302 |
|
Other funds holding VTVT
SB
SL
BBA
TECP
VCM
VFT
Morgan Stanley's VTVT Position: Q1 2026 in Review
Morgan Stanley increased its vTv Therapeutics (VTVT) stake by 18% in Q1 2026, buying an estimated $6.46K and bringing the position to 1,155 shares worth $45.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6452.
Morgan Stanley first reported a position in VTVT in Q3 2015 and has held it in 40 quarters since. The position peaked at $790K in Q3 2015. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.
- Morgan Stanley held 1,155 shares of vTv Therapeutics worth $45.8K as of Q1 2026.
- Morgan Stanley bought 178 vTv Therapeutics shares in Q1 2026, an estimated $6.46K.
- vTv Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6452 holding.
- Morgan Stanley first reported a position in vTv Therapeutics in Q3 2015 and has held it in 40 quarters since.
- Morgan Stanley's vTv Therapeutics position peaked at $790K in Q3 2015.
- 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.